Loading clinical trials...

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

The Comparison of the Efficacy and Safety of Arzoxifene Versus Raloxifene in Postmenopausal Women With Osteoporosis

NCT00383422•Eli Lilly and Company

Summary

The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).

Eligibility

Age

50 - 75 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Must have osteoporosis
•Must be between 50 and 75 years old and be able to walk
•Have at least two of your back bones that can be x-rayed
•Have not had a period in at least two years
•Be willing to have blood tests

Exclusion Criteria

•Have a bone disease other than osteoporosis
•History of estrogen dependent cancer
•History of stroke or certain heart problems
•Possibly have an allergy to raloxifene or arzoxifene
•Have certain abnormal lab values
•History of seizure disorder
•Have unexplained vaginal bleeding or an abnormal pap smear

Locations (21)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Gainesville, Georgia, United States

Urbandale, Iowa, United States

Billings, Montana, United States

Cincinnati, Ohio, United States

Houston, Texas, United States

Buenos Aires, Argentina

Randwick, New South Wales, Australia

Vancouver, British Columbia, Canada

Halifax, Nova Scotia, Canada

Toronto, Ontario, Canada

Key Dates

Start Date

October 1, 2006

Primary Completion Date

July 1, 2008

Completion Date

July 1, 2008

Last Updated

January 28, 2010

Enrollment

320

ACTUAL participants

Conditions

Osteoporosis, Postmenopausal

Interventions

Arzoxifene

DRUG

Raloxifene

DRUG

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

NCT05575167

Osteoporosis, Postmenopausal

View study

RECRUITINGNA

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

NCT05228262

Osteoporosis, Postmenopausal

View study

WITHDRAWNPHASE4

Effect of Mechanical Loading With PTH on Cortical Bone

NCT03232476

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 28, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

Inclusion Criteria

Exclusion Criteria

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

Effect of Mechanical Loading With PTH on Cortical Bone

A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)

A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)

Efficacy and Safety of MW031 in PMO Subjects